Full-Time

Staff Accountant

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$70.7k - $115.1k/yr

Junior, Mid

Tarrytown, NY, USA

Hybrid position requiring 3 days onsite per week.

Category
Auditing
Cost Accounting
Financial Accounting
Management Accounting
Accounting
Required Skills
Financial analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree with major in Accounting
  • 2+ years of accounting experience
  • Knowledge of Microsoft applications, specifically Microsoft Excel
  • Solid understanding of accounting principles
  • Experience with financial applications
Responsibilities
  • Lead the accounting of the Company’s global cash and investment processes
  • Perform monthly bank reconciliations, including the recording of various journal entries
  • Compile and present financial information to key stakeholders, including accounting management
  • Assist with the preparation of multiple SG&A expense schedules and balance sheet account reconciliations
  • Ensure compliance with the Company’s Prepaid Expense Accounting Policy
  • Perform fluctuation analyses and prepare responses for Management
  • Responsible for ensuring compliance with documented financial reporting and other related controls
  • Support internal and external audit with requests, as needed
  • Provide assistance to other departments within the organization with specific requests or initiatives related to area of responsibility
  • Assist with other special projects, analyses, and continuous improvement initiatives, as needed
Desired Qualifications
  • Public accounting experience
  • CPA license
  • Experience with Reval, Clearwater, Oracle GL, FCCS, Smartview and Hubble
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through licensing agreements, sharing costs and profits with partners in co-development projects. Unlike many competitors, Regeneron emphasizes strong research capabilities and strategic partnerships to stay ahead in the biopharmaceutical market. The goal of Regeneron is to improve patient outcomes by providing effective treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's Dupixent shows promise in treating bullous pemphigoid, a chronic skin disease.
  • AI-driven drug discovery could enhance Regeneron's R&D capabilities.
  • Strategic alliances with tech firms offer opportunities for technological advancements.

What critics are saying

  • Increased competition from companies like Amgen and AstraZeneca in similar treatment areas.
  • Regulatory challenges, such as delays in product approvals, pose significant risks.
  • Potential adverse events in trials could impact patient safety perceptions and approvals.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative drug development.
  • Strong collaborations with academic and research institutions enhance Regeneron's R&D efforts.
  • Regeneron's focus on targeted therapies aligns with the rise of personalized medicine.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PR Newswire
Mar 11th, 2025
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million To High School Seniors For Innovative Research On Classifying Celestial Objects, Treating A Rare Muscle Disease And Solving A Long-Standing Math Problem

$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competitionTARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.Congratulations to the top three Regeneron Science Talent Search award winners, Ava Grace Cummings, Matteo Paz and Owen Jianwen Zhang (left to right) Photo Credit: Chris Ayers Photography/Licensed by Society for ScienceNow in its 84th year, the competition celebrates and rewards young innovators who are applying their Science, Technology, Engineering and Math (STEM) talent and leadership skills to push the boundaries of discovery and address today's pressing challenges.Forty finalists, including Matteo, were honored this evening during an award ceremony at the National Building Museum in Washington, D.C, where they were awarded more than $1.8 million in prizes for their groundbreaking research, exceptional problem-solving skills and potential to shape the future of STEM.Matteo Paz , 18, of Pasadena, California , won first place and $250,000 for designing machine-learning algorithms to efficiently comb through 200 billion entries of raw NEOWISE infrared full-sky data. By analyzing tiny changes in infrared radiation, the AI sorted the objects into 10 classes. He found 1.5 million new potential objects.won first place and for designing machine-learning algorithms to efficiently comb through 200 billion entries of raw NEOWISE infrared full-sky data. By analyzing tiny changes in infrared radiation, the AI sorted the objects into 10 classes

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

MarketBeat
Mar 10th, 2025
American Assets Inc. Makes New $427,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

American Assets Inc. makes new $427,000 investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

PR Newswire
Mar 1st, 2025
Positive Results From Tezspire® (Tezepelumab-Ekko) Phase 3 Waypoint Trial Highlight Rapid, Sustained Effect In Chronic Rhinosinusitis With Nasal Polyps

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery. Data Published in NEJM and Presented at AAAAI/WAO 2025. THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for surgery and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) compared to placebo.1,2 The data were published today in the New England Journal of Medicine and were highlighted as a late-breaking oral presentation during the American Academy of Allergy Asthma Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego.1,2

RegMedNet
Feb 27th, 2025
Cell therapy weekly: world's first hospital-based autologous foundry

At the Research in Otolaryngology's 48th Annual MidWinter Meeting (22 - 26 February 2025; Orlando, FL), Regeneron Pharmaceuticals provided an update on the Phase I/II CHORD trial for DB-OTO, an investigational gene therapy for congenital hearing loss due to OTOF gene variants.